Journal
NEW JOURNAL OF CHEMISTRY
Volume 39, Issue 6, Pages 4852-4859Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5nj00309a
Keywords
-
Categories
Funding
- project Biological Properties and Biomedical Applications of Dendrimers
- European Regional Development Found
Ask authors/readers for more resources
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by the aggregation of extracellular beta-amyloid and the intracellular microtubule-associated protein Tau. Neurodegeneration is associated inter alia with the activation of microglial cells, neuroinflammation, oxidative stress, and diminished transduction of impulses in cholinergic neurons. Current pharmacotherapy for AD is based mainly on modulation of acetylcholine hydrolysis, administration of non-steroidal anti-inflammatory drugs and antioxidants. Novel drugs with antiamyloidic properties are currently being sought. Cationic phosphorus dendrimers have been proven to modulate amyloidogenesis and stop the aggregation of Tau protein. An ideal drug for AD should demonstrate anti-inflammatory properties, inhibit acetylcholine hydrolysis, and have antioxidant capacity. Cationic phosphorus dendrimers (generation 3 and generation 4) show the foregoing properties. They inhibit acetylcholinesterase activity, can decrease the secretion of TNF-alpha, and have weak antioxidant effects. The results presented suggest that phosphorus dendrimers may be considered in the future as agents in AD therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available